Few proponents of prostatic artery embolisation (PAE) regard it as a potential standard in future for benign prostatic obstruction (BPO) / benign prostatic hyperplasia (BPH) treatment. Present guidelines from the National Institute for Health & Care Excellence (NICE) and the Urological Society of Australia and New Zealand (USANZ) consider this an option only under a context of study or research. The procedure is well utilised in refractory prostatic bleeds in unfit patients at present. This single centre study looks at the benefit and safety of the procedure in patients with prostate volume more than 80gms and with Charlson’s comorbidity index > two. Other inclusion criteria were International Prostate Symptom Score (IPSS) >12, Qmax <15ml/s, and symptomatic BPO refractory to drugs. Exclusion criteria were neurogenic bladder, sphincter decompensation, coagulation disorders, anticoagulant / platelet therapy, chronic kidney disease (CKD), previous surgical or five-alpha reductase inhibitors (5ARI) treatment, life expectancy